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Effect of Phosphatidyl Inositol 3-Kinase, Extracellular
Signal-Regulated Kinases 1/2, and p38 Mitogen-Activated
Protein Kinase Inhibition on Osteogenic Differentiation
of Muscle-Derived Stem Cells
Karin A. Payne, Ph.D.,1,2 Laura B. Meszaros, B.S.,1–3 Julie A. Phillippi, Ph.D.,4 and Johnny Huard, Ph.D.1–3,5
Skeletal muscle-derived stem cells (MDSCs) can undergo osteogenesis when treated with bone morphogenetic
proteins (BMPs), making them a potential cell source for bone tissue engineering. The signaling pathways that
regulate BMP4-induced osteogenesis in MDSCs are not well understood, although they may provide a means to
better regulate differentiation during bone regeneration. The objective of this study was to characterize the
signaling pathways involved in the BMP4-induced osteogenesis of MDSCs. Cells were treated with BMP4 and
specific inhibitors to the extracellular signal-regulated kinases 1/2 (ERK1/2), p38 mitogen-activated protein
kinase (MAPK), and phosphatidyl inositol 3-kinase (PI3K) pathways (PD98059, SB203580, and Ly294002, re-
spectively). Cellular proliferation, expression of osteoblast-related genes, alkaline phosphatase (ALP) activity,
and tissue mineralization were measured to determine the role of each pathway in the osteogenic differentiation
of MDSCs. Inhibition of the ERK1/2 pathway increased ALP activity and mineralization, whereas inhibition of
the p38 MAPK pathway decreased osteogenesis, suggesting opposing roles of these pathways in the BMP4-
induced osteogenesis of MDSCs. Inhibition of the PI3K pathway significantly increased mineralization by
MDSCs. These findings highlight the involvement of the ERK1/2, p38 MAPK, and PI3K pathways in opposing
capacities in MDSC differentiation and warrant further investigation, as it may identify novel therapeutic targets
for the development of stem cell-based therapies for bone tissue engineering.
Introduction
Stem cells play a key role in embryonic development,organogenesis, and tissue regeneration in adults.1 Be-
cause of their self-renewal potential and ability to differen-
tiate toward various lineages, stem cells have become a key
component of tissue engineering approaches. Among the nu-
merous stem cell sources currently studied for their application
in regenerative medicine, one can include muscle-derived stem
cells (MDSCs). It is an early myogenic progenitor cell that
has been isolated from the mouse skeletal muscle using a
modified preplate technique.2,3 MDSCs have the ability to
differentiate toward skeletal muscle, neural, endothelial, and
hematopoietic tissues,3,4 and when treated with bone mor-
phogenetic protein 2 (BMP2) or BMP4, MDSCs are capable of
osteogenic and chondrogenic differentiation in vitro, have
been used for bone and cartilage formation in vivo, and show
promise in the developing field of bone and cartilage tissue
engineering.5–9
To undergo cellular differentiation toward a specific line-
age, all cells require the involvement of intrinsic signaling
pathways, which can be activated by extrinsic signals, such
as growth factors. BMPs are biological factors that play a key
role in the osteogenic and chondrogenic differentiation of
numerous cells in vitro and in vivo. The main BMP signaling
pathway utilizes signaling molecules known as Smads,10–12
although BMPs have been also shown to utilize other cell
signaling pathways such as the mitogen-activated protein
kinase (MAPK) cascades and the phosphatidyl inositol
3-kinase (PI3K).13–21
Inhibitory compounds have been widely used to elucidate
the role of the pathways they inhibit. Some of these com-
pounds are pyridinyl imidazole (SB203580) and 20-amino-30-
methoxyflavone (PD98059), which are inhibitors of the
MAPK cascades,22,23 and 2-(4-morpholinyl)-8-phenylchro-
mone (Ly294002), which inhibits the PI3K pathway.24
SB203580 specifically inhibits the MAPK family member
known as stress-activated protein kinase 2a, also known as
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p38.23 PD98059 binds to MAPK kinase 1 (MEK1), preventing
its activation by upstream proteins such as Raf, which makes
it unable to phosphorylate extracellular signal-regulated ki-
nases (ERK1/2).22 SB203580 thus inhibits the p38 MAPK
pathway, and PD98059 inhibits the ERK1/2 pathway.
Ly294002 binds to the ATP-binding site of PI3K, preventing
it from phosphorylating Akt and thus inhibiting the PI3K-
Akt pathway.24
The p38 MAPK pathway has been linked to osteogenesis
in cell types such as human osteoblastic cells,25,26 mouse MC3T3-
E1 preosteoblastic cells,27,28 and mouse C2C12 cells.14,29 Gallea
et al. showed that both the p38 MAPK and ERK1/2 cascades
are activated by stimulation of C2C12 cells with BMP2.14 In
this specific cell line, blocking the p38 MAPK pathway with
SB203580, a p38-specific inhibitor, led to a dose-dependent
decrease in alkaline phosphatase (ALP) activity, whereas in-
hibition of the ERK1/2 cascade by its selective inhibitor
PD98059 led to a slight increase in ALP activity. The PI3K-Akt
pathway has been also implicated in the differentiation of
osteoblasts, myoblasts, chondrocytes, and adipocytes.15,30–34
BMP2 can stimulate PI3K activity in osteogenic cells and its
inhibition with the specific inhibitor Ly294002 prevented
BMP2-induced ALP activity.15
BMP2 and BMP4 are highly homologous molecules, dif-
fering solely in their amino terminal region. Both can bind to
BMP receptors type I and type II, which come together to
enable BMP receptor type II to phosphorylate BMP receptor
type I, leading to Smad activation.10,35 Although many cell
signaling studies have been performed with BMP2 stimula-
tion, inhibitors such as PD98059, SB203580, or Ly294002 have
been also studied using BMP4.20,21,28,36–38 It has been shown
that BMP4-stimulated osteocalcin synthesis is negatively
regulated by ERK1/2, whereas p38 MAPK is a positive
regulator of its synthesis in MC3T3-E1 cells.36 BMP4-induced
ALP activity can be reduced in the same cells with SB203580,
also suggesting an important role of p38 MAPK in BMP4-
induced osteogeneis.28 Using Ly294002 on human multi-
potent mesenchymal stromal cells (MSCs), it was determined
that the PI3K pathway may play an important role in
endogenous BMP osteogenesis.21
To date, the signaling pathways involved in the BMP4-
induced osteogenic differentiation of MDSCs are not well
known. Elucidating the role of specific signaling pathways in
the BMP4-induced osteogenic differentiation of MDSCs may
allow for increased regulation of differentiation, which may
in turn lead to novel approaches to improve the role of
MDSCs for bone tissue engineering. Therefore, this study
tested the hypothesis that ERK1/2, p38 MAPK, and PI3K
pathways affect BMP4-induced osteogenic differentiation of
MDSCs by playing a role in their cell viability, expression
of osteoblast-related genes, ALP activity, and tissue miner-
alization.
Experimental Procedures
Isolation and culture of MDSCs
MDSCs were isolated from 3-week-old C57BL/10J mice
using a modified preplate technique.2,3 Cells were cultured
in phenol red-free proliferation medium (PM) consisting of
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen)
supplemented with 110mg/L sodium pyruvate (Sigma-
Aldrich), 584mg/L l-glutamine, 10% fetal bovine serum,
10% horse serum, 1% penicillin/streptomycin (all from In-
vitrogen), and 0.5% chick embryo extract (Accurate Chemical
Co.) at 378C in a humidified atmosphere of 5% CO2 in air. To
determine the minimal dose of BMP4 necessary to have an
effect on ALP activity and Alp gene expression, MDSCs were
plated at a density of 1500 cells/cm2 and, on the following
day, were treated with BMP4 (0, 50, 100, or 200 ng/mL). All
subsequent monolayer assays in this study began with cells
plated at a density of 1500 cells/cm2 and, on the following
day, were treated with or without the optimized concentra-
tion of BMP4 (50 ng/mL) and the inhibitors PD98059 (Biomol
International), SB203580 (Biomol International), or Ly294002
(Cell Signaling), which are specific inhibitors for the ERK1/2,
p38 MAPK, and PI3K pathways, respectively. Inhibitors
were dissolved in dimethyl sulfoxide before use, and control
cultures received a concentration of 25mM of dimethyl sulf-
oxide, which is equivalent to the highest concentration found
in the treated cultures. In all assays, cells were incubated
with the inhibitors for 1 h before addition of BMP4.
Cell viability
Cell viability was measured in 96-well microtiter flat-
bottomed plates. Inhibitors were tested at concentrations of
25 mM (PD98059 and SB203580) or 10mM (Ly294002) and
medium was refreshed every 48 h (100 mL/well). The inhib-
itor concentrations were chosen based on previously pub-
lished studies14,17 and preliminary data. Cell viability was
assayed with the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) after 4 days of treatment. At
the end of the assay, 20mL of CellTiter 96 AQueous One
Solution reagent was added to each well, the plate was in-
cubated for 2 h at 378C in a humidified, 5% CO2 incubator,
and the absorbance was measured at 490 nm.
Quantitative polymerase chain reaction analysis
of osteogenic genes
MDSCs were treated as described above for 24 h, after
which total RNA was collected using the RNeasy kit
(Qiagen). Quantitative real-time PCR (qPCR) analysis was
performed with Taqman One-step RT-PCR Master Mix
(Applied Biosystems) as described previously.39 RNA sam-
ples (1mL) were added to sequence-specific primers and
Taqman probes (200 nM per 10 mL reaction) for Alp, Runx2,
and Osterix (Osx) genes. All target genes were normalized to
18S (primers and probe from Applied Biosystems). The se-
quences of the target gene primers and probes were previ-
ously published.39 All target gene probes were labeled with
FAM as the 50 reporter dye and TAMRA as the 30 quencher
dye. qPCR assays were carried out in triplicate on an ABI
Prism 7900HT sequence detection system in the core facility
of the Genomics and Proteomics Core Laboratories of the
University of Pittsburgh. Data were analyzed using SDS 2.1
Software from Applied Biosystems.
ALP activity
For ALP enzymatic activity, MDSCs were treated with
BMP4 in the presence or absence of the inhibitors PD98059
(25 mM), SB203580 (25 mM), or Ly294002 (10mM), as described
above. Three days after initiation of treatment, the cells were
washed once with phosphate-buffered saline, lysed in 0.1%
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Triton-X in water, and assayed using SIGMA FAST
p-nitrophenyl phosphate tablets (N-2770; Sigma-Aldrich).
Diluted samples of cell lysate were incubated with
p-nitrophenyl for 30min in the dark at room temperature.
Following this incubation, absorbance at 405 nm was deter-
mined. Total protein was also calculated by assaying diluted
samples of cell lysate using the Micro BCA protein assay
(Pierce) according to manufacturer’s instructions. ALP ac-
tivity was normalized per mg protein and expressed as na-
nomoles of p-nitrophenyl liberated per microgram of total
cellular protein.
Osteogenic pellet culture
To test mineralization, 250,000 MDSCs were cultured as
pellets, as previously described,40 in osteogenic medium
(OSM) containing phenol red-free DMEM supplemented
with 110mg/L sodium pyruvate, 584mg/L l-glutamine,
10% fetal bovine serum, 1% penicillin/streptomycin, 107M
dexamethasone, 5105M ascorbic-acid-2-phosphate, and
102M b-glycerophosphate and with BMP4 (100 ng/mL) in
the presence or absence of pathway inhibitors (25mM
PD98059, 25 mM SB203580, and 10 mM Ly294002) for 21 days.
Medium was replaced every 3 days. Preliminary data testing
different doses of BMP4 on pellet cultures indicated that
BMP4 at a concentration of 100 ng/mL was necessary to in-
duce a measurable amount of mineralization in the MDSC
population used in this study. To assess mineralization, all
pellets were analyzed at 14 and 21 days using a mCT imaging
system (vivaCT 40; Scanco Medical) with the following set-
tings: 55 kVp of energy, 200ms integration time, and an
isotropic voxel size of 10.5 mm.40 Two-dimensional image
slices were obtained and contour lines were drawn to define
the volume of interest. An appropriate threshold was chosen
for the bone voxels by visually matching thresholded ar-
eas to grayscale images. The threshold was kept constant
throughout the analyses of each pellet. This led to a three-
dimensional (3D) reconstruction of the mineralized tissue
within the pellets and provided quantitative data on min-
eralized tissue volume (mm3) and density (mg hydroxy-
apatite [HA]/cm3). In a subsequent experiment, pellets were
made and treated with BMP4 for 21 days, but were only
treated with pathway inhibitors for the first 7 days of culture.
Statistical analysis
All in vitro monolayer experiments (cell viability, qPCR,
and ALP activity) were performed in triplicate and repeated
three times. One representative experiment is reported as the
mean of three treatment replicates standard error of mean.
For osteogenic pellet culture experiments, data represent
four pellets per treatment group. Data for Figures 1, 2, 4, and
5 were analyzed using a one-way, between-subjects analysis
of variance and Tukey post hoc analysis. Data for Figure 3
were analyzed using Student’s t-tests for each comparison
(with and without inhibitor). Data for Figure 6 were ana-
lyzed using separate (for volume and density, respectively)
two-way, within-subject analysis of variance and Tukey post
hoc analysis. All analyses were performed with SPSS statis-
tical software. A p-value of <0.05 was considered significant.
Results
Response of MDSCs to BMP4 stimulation
Twenty-four hours after the initiation of BMP4 treatment
(50, 100, or 200 ng/mL), a dose response was observed for
Alp gene expression and ALP activity. Both were signifi-
cantly higher than untreated control at all BMP4 concen-
trations tested (Fig. 1a, b, *p< 0.05). The lowest BMP4
concentration necessary to have a significant effect on
MDSCs, 50 ng/mL, was chosen for all other assays involving
monolayer culture.
Effect of pathway inhibitors on cell viability
Specific inhibitors to the ERK1/2, p38 MAPK, and PI3K
pathways were added to untreated (control) or BMP4-treated
MDSCs and the cell viability was measured after 4 days (Fig.
2). Cell viability was not significantly increased in BMP4-
treated cells compared with untreated control cells. Inhibi-
tion of the ERK1/2 pathway had no effect on the viability of
MDSCs (Fig. 2a), and inhibition of the p38 MAPK pathway
similarly did not affect MDSC viability (Fig. 2b). Inhibition of
the PI3K pathway in MDSCs displayed a significant decrease
in cell viability and this was evident when both control cells
and BMP4-treated cells were incubated with the pathway
inhibitor (Fig. 2c, *p< 0.05 vs. control, #p< 0.05 vs. BMP4).
FIG. 1. Response of muscle-derived stem cells (MDSCs) to bone morphogenetic protein 4 (BMP4) stimulation (0–200 ng/
mL). (a) Alp gene expression at 24 h after initiation of BMP4 stimulation. (b) Alkaline phosphatase (ALP) activity at 3 days
after initiation of BMP4 stimulation. Bars represent mean standard error of mean (SEM); n¼ 3. *p< 0.05 compared with
control.
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Effect of pathway inhibitors
on osteogenic differentiation
Osteogenic gene expression. Inhibition of the ERK1/2
pathway by addition of PD98059 to BMP4-treated MDSCs
did not show a significant effect on Alp, Runx2, or Osx gene
expression (Fig. 3a). However, a trend of increased fold
change over BMP4 treatment only was observed for both Alp
and Runx2 gene expression (Fig. 3a). A significant decrease
in Alp gene expression was seen as a result of inhibiting the
p38 MAPK pathway during BMP4 stimulation (Fig. 3b,
*p< 0.05). A decrease in Osx gene expression upon addition
of SB203580 to BMP4 was also observed, as levels were
nondetectable by qPCR (Fig. 3b, N/D). Following inhibition
of the PI3K pathway with Ly294002, an increase in Alp,
Runx2, and Osx gene expression was observed in compari-
son to BMP4 treatment only (Fig. 3c). This increase was
statistically significant for Runx2 and Osx gene expression
(Fig. 3c, *p< 0.05).
ALP activity. Inhibition of the ERK1/2 pathway led to a
significant increase in ALP activity in MDSCs that were
treated with BMP4 (Fig. 4, *p< 0.05 vs. BMP4). The opposite
was seen with inhibition of the p38 MAPK pathway, where a
significant decrease in ALP activity was found (Fig. 4, *p<
0.05 vs. BMP4). Inhibition of the PI3K pathway in BMP4-
treated MDSCs significantly decreased ALP activity (Fig. 4,
*p< 0.05 vs. BMP4).
Mineralization. Cell pellets are shown in Figure 5a. From
macroscopic observation, pellets cultured with BMP4 and
the inhibitor to either the ERK1/2 or the PI3K pathway ap-
pear less translucent than pellets that received BMP4 only or
BMP4 and the inhibitor to the p38 MAPK pathway. These
FIG. 2. Cellular viability of MDSCs with or without BMP4
stimulation (50 ng/mL) and inhibition of the (a) extracellular
signal-regulated kinases 1/2 (ERK1/2), (b) p38 mitogen-
activated protein kinase (MAPK), and (c) phosphatidyl ino-
sitol 3-kinase (PI3K) pathways. Bars represent mean SEM;
n¼ 3. *p< 0.05 compared with control. #p< 0.05 compared
with BMP4.
FIG. 3. Alp, Runx2, and Osx gene expression in MDSCs
treated with BMP4 (50 ng/mL) in the presence or absence of
the inhibitors to the (a) ERK1/2, (b) p38 MAPK, and (c) PI3K
pathways. Bars represent mean SEM; n¼ 3. *p< 0.05 com-
pared with BMP4.
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differences were quantified by mCT analyses to obtain min-
eralized tissue volume and density. The pellets treated with
BMP4 and inhibitors to the ERK1/2 and PI3K pathways had
significantly more mineralized tissue volume (Fig. 5b,
*p< 0.05 vs. OSMþBMP4) and density (Fig. 5c, *p< 0.05 vs.
OSMþBMP4) than the pellets treated with BMP4 only. In-
hibition of the p38 MAPK pathway significantly decreased
mineralized tissue volume (Fig. 5b, *p< 0.05 vs. OSMþ
BMP4). However, mineralized tissue density was not affected
(Fig. 5c).
To determine whether a sustained inhibition of the path-
ways was necessary to affect mineralization, pellets were
treated with BMP4 for the 21-day duration of the experiment,
but were treated with inhibitors to specific pathways for only
the first 7 days of culture. mCT analysis showed that the
pellets that received the inhibitor to the ERK1/2 pathway for
7 days had significantly greater mineralized tissue volume
and density than the pellets that were treated with BMP4
only, and this increase remained after 21 days of pellet cul-
ture (Fig. 6a, b, *p< 0.05 vs. OSMþBMP4). Inhibition of the
p38 MAPK pathway for the first 7 days of pellet culture
showed a significant decrease in mineralized tissue volume
and density compared with BMP4 treatment only at 14 days
(Fig. 6a, b, *p< 0.05 vs. OSMþBMP4). Interestingly, there
was a significant increase in mineralization in this group
between 14 and 21 days of culture, making it no longer
different from control (Fig. 6a, b, #p< 0.05 vs. 14 days). Un-
like continuous inhibition of the PI3K pathway for 21 days,
inhibition of this pathway for only the first 7 days of pellet
culture did not lead to differences in mineralized tissue
volume or density compared with the pellets treated with
BMP4 only (Fig. 6a, b).
A summary of all these results has been included in
Table 1 to provide an overview of the effect of each pathway
on the osteogenic differentiation of MDSCs.
Discussion
In this study, the BMP4 signaling of MDSCs was charac-
terized by studying an MDSC population that readily un-
dergoes osteogenic differentiation when treated with BMP4.
By taking advantage of specific chemical inhibitors to the
ERK1/2, p38 MAPK, and PI3K pathways, such as PD98059,
SB203580, and Ly294002, respectively, it was possible to
elucidate the involvement of these different pathways in the
BMP4-induced osteogenesis of MDSCs.
FIG. 4. ALP activity of MDSCs treated with BMP4 (50 ng/
mL) and inhibitors to the ERK1/2, p38 MAPK, and PI3K
pathways for 3 days. Bars represent mean SEM; n¼ 3.
*p< 0.05 compared with BMP4.
FIG. 5. Osteogenic pellet culture of MDSCs treated with BMP4 (100 ng/mL) and inhibitors to the ERK1/2, p38 MAPK, and
PI3K pathways for 21 days. (a) Macroscopic images of MDSC pellets (1mm scale). (b) Volume of mineralized tissue and (c)
density of mineralized tissue determined by mCT analysis. Bars represent mean SEM; n¼ 4 pellets/group. *p< 0.05 com-
pared with osteogenic medium (OSM)þBMP4. Color images available online at www.liebertonline.com/ten.
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In studying the osteogenic differentiation of MDSCs in-
duced by BMP4, it was also important to determine how this
growth factor affected cell metabolic activity, and the in-
volvement of the different pathways analyzed in this study.
However, when BMP4 was added to the PM, the MDSC
population used was unaffected. This may be explained by
an inverse relationship between proliferation and differen-
tiation, where molecules that promote differentiation may
also prevent cell cycle reentry. Although MDSCs readily
responded to BMP4 by undergoing osteogenic differentia-
tion, they did not increase their proliferation. By using che-
mical inhibitors, it was determined that the viability of
MDSCs was affected by inhibition of the PI3K pathway but
not by inhibition of the p38 MAPK or ERK1/2 pathway.
Activation of the PI3K/Akt signaling pathway by growth
factors leads to the phosphorylation of the BCL-2 family
member BAD, which in turn prevents apoptosis and pro-
motes cell survival.41,42 Activation of the ERK1/2 pathway
also follows a similar mechanism.43 Reduced viability was
thus expected after blockade of the PI3K signaling pathway
with Ly294002 or inhibition of the ERK1/2 signaling path-
way with PD98059. On the other hand, activation of p38
MAPK is known to induce exit from the cell cycle and to
lead to the differentiation of various cell types.44,45 Its inhi-
bition by SB203580 has increased the proliferation of mam-
malian cardiomyocytes, although these cells are considered
terminally differentiated and incapable of proliferation.46 In
the MDSCs used in this study, reduced cellular viability was
only seen with Ly294002 and has previously been reported
in other adult muscle cells.47 Inhibition of the ERK1/2 and
p38 MAPK pathways may not play a significant role in the
cellular viability of MDSCs, or a higher concentration of the
inhibitors may be needed to have an effect.
The role of the ERK1/2, p38 MAPK, and PI3K pathways
was also investigated with respect to the role they play in the
osteogenic differentiation of MDSCs. Genes such as Alp,
Runx2, and Osx were investigated, as they are key early in-
dicators of osteogenic differentiation. The inhibition of the
ERK1/2 pathway during BMP4 stimulation did not signifi-
cantly affect osteogenic gene expression, although it showed
a trend toward increasing Alp compared with BMP4 treat-
ment only. It did, however, increase ALP activity after 3 days
of stimulation with BMP4. This effect has been also shown in
C2C12 cells and human MSCs, suggesting that high ERK
activity negatively regulates BMP stimulation of ALP.14,17 In
the present study, the effect of pathway inhibitors on matrix
mineralization was also studied. Inhibition of the ERK1/2
pathway in BMP4-treated MDSCs affected mineralization by
significantly increasing it, compared with BMP4 treatment
only. The BMP4-induced synthesis of osteocalcin, a bone-
type extracellular matrix protein, in MC3T3-E1 cells has
been increased by inhibition of the ERK1/2 pathway with
Table 1. Overview of the Effect of Different Pathway Inhibitors on the Bone Morphogenetic
Protein 4-Induced Osteogenic Differentiation of Muscle-Derived Stem Cells
Assay results
Gene expression
Inhibitor used Pathway inhibited Proliferation Alp Runx2 Osx ALP activity Mineralization
PD98059 ERK1/2 — : : — :a :a
SB203580 p38 MAPK — ;a — ;a ;a ;a
Ly294002 PI3K ;a : :a :a ;a :a
aIncrease or decrease that is statistically significant ( p< 0.05).
ALP, alkaline phosphatase; ERK, extracellular signal-regulated kinases; MAPK, mitogen-activated protein kinase; PI3K, phosphatidyl
inositol 3-kinase.
FIG. 6. Osteogenic pellet culture of MDSCs treated with BMP4 (100 ng/mL) for 21 days and inhibitors to the ERK1/2, p38
MAPK, and PI3K pathways for the first 7 days of culture. (a) Volume of mineralized tissue and (b) density of mineralized
tissue determined by mCT analysis. Bars represent mean SEM; n¼ 4 pellets/group. *p< 0.05 compared with OSMþBMP4.
#p< 0.05 compared with 14 days.
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PD98059,36 suggesting that the ERK1/2 pathway is a nega-
tive regulator of osteogenesis. The role of ERK1/2 as a
negative regulator of matrix mineralization has been also
recently shown in human MSCs in a 3D collagen type I
culture48 and in an in vivo calvaria model.49 Interestingly, the
present study showed that when the pathway was inhibited
in BMP4-treated pellets for only 7 days and the pellets then
cultured with BMP4 only, the increased mineralization was
still evident at 21 days. This suggests that blocking the
ERK1/2 pathway at early time points during osteogenesis
may be important to promote mineralization. The continued
increase in mineralization over time indicates that pretreat-
ment of cells with PD98059 may be sufficient to promote
bone formation, a technique that may be valuable in the
development of novel bone tissue engineering approaches.
From the results presented in this study, the ERK1/2 path-
way was found to be a negative regulator of the BMP4-
induced osteogenesis of MDSCs.
Studies investigating the role of the p38 MAPK pathway
in osteogenic differentiation are at times conflicting. A report
on the inhibition of p38 MAPK activity in C2C12 cells treated
with BMP2 showed an increased osteogenic effect, suggest-
ing an inhibitory role of p38 MAPK on osteogenesis.29
In other studies that employed either BMP2 or BMP4 on
primary calvarial osteoblasts, primary bone marrow osteo-
progenitor cells, normal human osteoblasts, or the murine
osteoblast line MC3T3-E1, it was found that p38 MAPK is
necessary for BMP-induced osteogenic differentiation.25–28,36,50
Recently, it has been also found that the p38 MAPK pathway
plays a positive role in BMP-induced Osx expression.51,52 In
the present study on MDSCs, Alp and Osx gene expression
was also shown to be dependent on p38 MAPK activation.
Mineralization of MDSCs was decreased as a result of p38
MAPK inhibition, again suggesting that the p38 MAPK
pathway is necessary for the osteogenic differentiation of
MDSCs. This was further confirmed when the p38 MAPK
pathway was inhibited in BMP4-treated MDSC pellets for
only 7 days. Although a decrease in mineralization was ev-
ident at 14 days, mineralization recovered and approached
that seen in MDSC pellets that received BMP4 only stimu-
lation for 21 days. Hence, MDSCs that had the p38 MAPK
pathway initially inhibited were able to undergo minerali-
zation once the inhibition was removed.
The PI3K pathway has not been as widely studied as the
MAPK pathways in BMP signaling, especially its role in
matrix mineralization. In MDSCs, at the gene expression le-
vel, inhibition of the PI3K pathway increased the expression
of Runx2 and Osx, whereas Alp gene expression was not
significantly affected. At the protein level, ALP activity was
significantly decreased when PI3K was inhibited in BMP4-
treated cells. This decrease in BMP-stimulated ALP activity
with Ly294002 is in accordance with previous studies uti-
lizing BMP2 on human MSCs and mouse calvaria cells15,17 or
endogenous BMPs, including BMP4, on human MSCs.21
However, the nonsignificant effect of Ly294002 on Alp gene
expression after BMP stimulation is not in accordance with
previous studies.17,21 The reason why Ly294002 may not
have had an effect on the expression of Alp, but decreased
ALP activity, may be due to the timing of the assays. Gene
expression was measured after 24 h of stimulation, whereas
ALP activity at the protein level was measured after 3 days.
The effect of Ly29402 on gene expression may have occurred
earlier or later than 24 h and may have caused it to be dif-
ferent than the protein level. Another interesting finding in
this study is that when MDSCs were cultured as pellets in
OSM, the inhibition of the PI3K pathway significantly in-
creased matrix mineralization when compared with BMP4
only treatment. This suggests that PI3K may play a negative
role in matrix mineralization. This finding is in accordance
with that seen in vascular smooth muscle cells, where Akt
signaling was found to have an inhibitory activity on the
matrix calcification of these cells.53 Interestingly, inhibition of
the PI3K pathway for only 7 days in MDSCs cultured as
pellets in OSM did not affect mineralization. Thus, a con-
tinuous inhibition may be necessary. Taken together, the
findings from this study suggest that PI3K may play a role in
the BMP4-induced osteogenic differentiation of MDSCs, al-
though more studies are necessary to elucidate its role in Alp
gene expression. PI3K was found to play an important role in
matrix mineralization and may be a potential target to pro-
mote bone formation in tissue engineering approaches.
Many chemical inhibitors are commercially available, al-
though they may have different affinities for certain protein
kinases.54 The inhibitors PD98059, SB203580, and Ly294002
are commonly used in the literature and were thus selected
for this study, although other inhibitors could be used in
their place.54 PD184352 and U0126 could be used instead of
PD98059. SB202190 is structurally similar and has a similar
specificity to SB203580. In addition to Ly294002, the PI3K
pathway can also be inhibited by Wortmannin and Querce-
tin. Future studies on MDSCs could use these different che-
mical inhibitors to more clearly define the role of the ERK1/
2, p38 MAPK, and PI3K pathways on BMP4-induced osteo-
genesis. It should also be noted that chemical inhibitors
could affect more than one pathway because of cross-talk
between pathways. ERK1/2, p38 MAPK, and PI3K have all
been linked with BMP-activated Smads.15,17,26,55 As well,
different cell types may respond differently to BMPs and
pathway inhibitors. Thus, the role of these signaling path-
ways in BMP-induced osteogenesis is not a clearly defined
process, but can be complicated by their individual and co-
operative roles in the regulation of osteogenic markers.
This study was the first step toward understanding how
BMP4 signals in MDSCs. By using well-established chemical
inhibitors to the ERK1/2, p38MAPK, and PI3K pathways, we
demonstrated that the ERK1/2 pathway plays an inhibitory
role in the osteogenic differentiation of MDSCs, especially in
their mineralization. On the other hand, the p38 MAPK
pathway plays an important stimulatory role in osteogenesis.
Another interesting finding in this study is that the PI3K
pathway may play an inhibitory role in the matrix minerali-
zation of MDSCs. Future studies may involve precondition-
ing MDSCs with the ERK1/2 pathway inhibitor to increase
their osteogenic differentiation in vitro and potentially en-
hance their ability to form bone in vivo. The inhibition of
the PI3K pathway may also be a potential target. These
studies will be especially useful to increase the matrix for-
mation of cells that show less than optimal osteogenic po-
tential. Therefore, further investigation into how the ERK1/2,
p38 MAPK, and PI3K pathways affect MDSC differentiation
inmonolayer, pellet culture, or other 3D environments such as
tissue engineering scaffolds is warranted, as it may identify
novel therapeutic strategies for the development of stem cell-
based therapies for bone tissue engineering.
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